English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Cord Blood America Licenses Technology to Chinese AXM Pharma

Mar. 30, 2010

Cord Blood America, Inc. (“CBAI”) has announced on March 31, 2010 the signing of a License and Cooperation Agreement with Chinese AXM Pharma, Inc., a China pharma and nutraceutical company.
According to the agreement, CBAI will grant AXM a license to use its proprietary technology and know-how for the processing and storage of cord blood, as well as provide consulting and training. In return, CBAI will receive a 10% equity stake in AXM Pharma's stem cell subsidiary and an 8.5% royalty for all cord blood sales.
The companies plan to begin processing stem cell samples by January 1, 2011, subject to receipt of regulatory approvals.